# Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

> **NCT06329570** · PHASE1,PHASE2 · RECRUITING · sponsor: **NaviFUS Corporation** · enrollment: 10 (estimated)

## Conditions studied

- Glioblastoma Multiforme
- Glioblastoma
- Glioma
- Brain Tumor
- Neoplasms
- Neoplasms, Nerve Tissue

## Interventions

- **DEVICE:** NaviFUS System
- **DRUG:** Lumason
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06329570
- **Lead sponsor:** NaviFUS Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-22
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06329570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06329570, "Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06329570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*